Review on zolgensma
Milestone in spinal muscular atrophy
Keywords:
genetic disorder, spinal muscular atrophy, survival motor neuron, gene therapy, zolgensmaAbstract
Disease and disorders are outlined as disablement of the normal state of living organism and annoyance of normal functioning of the body respectively. The ideal causes of the disorders are genetic factors, disease, stress or trauma. Genetic disorders are a pathological state provoked by one or more monstrosities in the genome. Spinal Muscular Atrophy is a rare genetic disease and most common monogenic cause of infant mortality. Hypotonia and weakness are most common manifestations of Spinal Muscular Atrophy delineated by degeneration of anterior horn cells of the spinal cord. SMA is originated due to mutations and deletions of SMN1 (Survival Motor Neuron) gene on Chromosome 5q. Disease modifying therapy and Gene replacing therapy are the common gene therapy used to treat genetic disorders. Zolgensma is an Adeno virus associated gene therapy restored a gene which is functional one. Children under the age of 2 are benefited from a single time intravenous (IV) infusion of Zolgensma. In future Gene therapy can treat all the illness associated with Genetic disorders.
Downloads
References
Scrpelli, Dante G, and Burrows, William "Disease" Encyclopaedia, Britannica, 6 March 2020.
Kennedy's disease Physiopedia.
Dolgin, Elie (2019). News Feature: Gene therapy successes point to better therapies. Proceedings of the National Academy of Sciences, 116(48), 23866–23870. doi:10.1073/pnas.1918306116
https://www.rarediseaseadvisor.com/disease-info-pages/spinal-muscular-atrophy/
Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015 Nov;33(4):831-46. doi: 10.1016/j.ncl.2015.07.004. PMID: 26515624; PMCID: PMC4628728.
Broekhoff TF, Sweegers CCG, Krijkamp EM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG, Vreman RA. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value Health. 2021 Jun;24(6):759-769. doi: 10.1016/j.jval.2020.09.021. Epub 2021 Mar 31. PMID: 34119073.
https://my.clevelandclinic.org/health/diseases/14505-spinal-muscular-atrophy-sma
Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012 Jan;46(1):1-12. doi: 10.1016/j.pediatrneurol.2011.09.001. PMID: 22196485.
Overview of the ZOLGENSMA clinical studies, 2020.
Debra Stevens, Melanie K.Claborn, Brooke L.Gildon, Tiffany L.Kessler, Cheri walker, Onasemnogene abeparvovec-xioi: Gene therapy for spinal muscular atrophy, Annals of pharmacotherapy, 2020: 1-9.
Joshua Cohen, At over $2million Zolgensma is the world’s most expensive therapy yet relatively cost effective, Forbes, 2019.
Tamara dangouloff, Laurent servais, Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives, Ther Clin Risk Manag, 2019: 15: 1153-1161.
Lisa Urquhart, FDA new drug approvals in Q2 2019, Nature reviews drug discovery, 2019: 18(8): 575-576.
“Explained: Why world’s most expensive drug Zolgensma cost Rs.18cr?”, https://www.factchecker.in/amp/explained/zolgensma-worlds-most-expensive-drug-approved-by-nhs-costs-rs-18-crore-in-india-735002.
Amber R.Watson, Zolgensma (Onasemnogene abeparvovec-xioi), 2021.
“ZOLGENSMA dosage and Rx info/ uses, side effects”, https://www.empr.com/drug/zolgensma/
Novartis stands behind Zolgensma® (Onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy, 2019.
Joerg Reinhardt et al, Avexis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular, 2019.
Overview of the ZOLGENSMA clinical studies, 2020.
“Zolgensma for the treatment of spinal muscular atrophy, Novartis”, https://www.clinicaltrialsarena.com/projects/zolgensma/
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post treatment, 2021, https://www.novartis.com
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
